OncoMatch/Clinical Trials/NCT06959706
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Is NCT06959706 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TGW101 for advanced solid tumors.
Treatment: TGW101 — The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Refractory disease, intolerance to, or documented refusal of available standard therapy(ies) known to provide clinical benefit for the participant's solid tumor malignancy per Investigator judgment
Cannot have received: anticancer therapy
Anticancer therapy within 28 days or within 5 half-lives (whichever is shorter) prior to starting study drug
Cannot have received: palliative radiation therapy
Palliative radiation therapy within 14 days prior to starting study drug
Cannot have received: high-dose chemotherapy requiring stem cell rescue
Prior high-dose chemotherapy requiring stem cell rescue
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Massachusetts General Hospital · Boston, Massachusetts
- University of Texas MD Anderson Cancer Center · Houston, Texas
- NEXT Dallas · Irving, Texas
- NEXT San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify